Activeted-379135-2026

Emicizumab Active Substance Supply for Hemophilia Treatment Centers

Seeking the supply of the active substance Emicizumab, including administration kits, for 2026-2028 to ensure treatment continuity for patients with Factor VIII deficiency. This includes home delivery logistics and disposal of single-use materials for approximately 961,368 mg.

View original source

CONTRACTING AUTHORITY

Name

Instytut Matki i Dziecka

City

Warszawa

Country

CLASSIFICATION

Procedure Type

Open Procedure

Contract Type

Supplies

Main CPV

33621000, Medicinal products for the blood and blood-forming organs.

ADDITIONAL DETAILS

EU Funded

Yes

Electronic Submission

Required

Legal Basis

32014L0024

DEADLINES & TIMELINE

Submission Deadline

07/03/202609:00 AM Uhr28 days remaining

(LOT-0001)

Published

06/02/2026

TENDER DOCUMENTS

28 days remaining

Similar Tenders

Explore CPV 33

Medical Products, Immunoglobulins, and Dressings for EB Patients

Procurement of medical products, immunoglobulins, and dressings for patients with Epidermolysis bullosa (EB). Detailed specifications and contract terms are provided in the annexes.

Instytut Matki i Dziecka

·Warszawa

Deadline:July 02, 2026

Chemicals and Reagents for DNA/RNA Analysis and Next-Generation Sequencing for the Institute of Mother and Child

Procurement of chemicals, reagents for DNA/RNA analysis, DNA isolation kits, and supplementary reagents for next-generation sequencing. Detailed specifications and contract terms are provided in the annexes.

Instytut Matki i Dziecka

·Warszawa

Deadline:June 29, 2026